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**Web appendix 1:** Derivation of models of mortality rates as a function of age

###### 

Click here for additional data file.
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**Web appendix 2:** Complete abstracted dataset from vital statistics sources
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**Web appendix 3:** Associations between ischaemic heart disease mortality and female breast cancer mortality in US birth cohorts
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Click here for additional data file.

Introduction
============

The relative delay in the onset of ischaemic heart disease in women compared with men, on a population level, has been attributed largely to the putative protective effects of the premenopausal hormonal milieu, but little epidemiological or clinical evidence supports this.[@ref1] Circulating lipids have been shown to change levels during the menopausal transition,[@ref2] but interpretation of these changes is made complex by discrepant changes in the levels of cholesterol and apolipoprotein.[@ref3] Ischaemic heart disease mortality increases with age, but cross sectional analyses of age specific mortality have not shown any sudden proportional acceleration at the age of menopause in women, either in data from England and Wales,[@ref4] the United States,[@ref5] or Japan.[@ref6] By contrast, the proportional increase in breast cancer mortality with age abruptly decelerates at menopausal age among women.[@ref1] [@ref7]

Two issues need resolution with respect to previous cross-sectional analyses. Firstly, it is not known why age related mortality should be examined on the proportional (or logarithmic) scale for ischaemic heart disease mortality, rather than an absolute age related increase in mortality, which accelerates throughout adult life in both men and women. By contrast, the accumulation of multiple injuries has been suggested as a mechanistic explanation for a proportional increase in cancer related mortality with age.[@ref7] Secondly, ischaemic heart disease has a long latency period before death, and in view of changing lifestyles and treatment environments over a person's lifetime, it is difficult to interpret cross sectional associations between age and mortality.

The dual goal of this analysis was to challenge existing paradigms regarding causality attribution to menopause as it relates to the risk of ischaemic heart disease in women, by providing a mechanistic hypothesis for proportional increases in mortality, and applying it to longitudinal vital statistics data. To do this, we aimed to show that a proportional change in mortality is biologically and numerically meaningful, possibly representing a constant probability of the failure of tissue reparative cells across a lifetime.[@ref8] [@ref9] Indeed, the length of telomeres in circulating leucocytes, which can be taken as a proxy for other bone marrow cells that replenish the circulatory system, reduces linearly during adult life.[@ref10] Because telomere length shortens linearly with every cell division, the linear loss of telomere length over adult life[@ref10] indicates that, on average, cells divide at a constant rate over time. Loss of telomere length limits a cell's capacity to replicate.[@ref11] Therefore, regeneration of bone marrow cells is limited in a linear fashion with increasing age. This explanation is a generalisation of the cancer specific process proposed by Pike and colleagues[@ref7] to all senescent chronic disease, and is based on age related heart disease mortality among birth cohorts (born 1916-45) in England and Wales[@ref12] and the United States.[@ref13]

Methods
=======

Mortality models as a function of age
-------------------------------------

Model 1 assumes a linear association between mortality rates and age (absolute mortality). Indeed, this model is implicit in the statement of the current hypothesis that the increase in absolute heart disease mortality accelerates at menopause. Such a model would suggest that the upward slope of absolute mortality versus age is roughly constant before menopause, and would change to a different slope around the time of menopause in women.

> Mortality rate=β~0~+β~1~×age in years+β~2~×(time since menopause in years)
>
> (where β~0~=intercept, β~1~=linear slope with respect to age, and β~2~=change in slope after menopause; if there is no change in slope at menopause, β~2~ estimate=0)

Model 2 assumes a proportional (or logarithmic) association between mortality and age. Survival of an organism results from an ongoing repair of tissue injury that is dependent on a pool of repair mechanisms (for example, regenerative repair cells). Ageing is thought to be a result of loss of this pool. If the probability of removal of these reparative cells due to cell division is constant over time, the reparative reserve is lost at a constant proportion with age. Using the derivation in web appendix 1, we obtained the following model:

> log(mortality rate)=β~0~+β~1~×age in years+β~2~×(time since menopause in years)
>
> (where β~0~=intercept, β~1~=linear slope with respect to age, and β~2~=change in slope after menopause; if there is no change in slope at menopause, β~2~ estimate=0)

Therefore, we can interpret modelling changes in proportional mortality in model 2, rather than absolute mortality as in model 1, as changes in reparative demands on a decreasing reserve of repair mechanisms (for example, stem cells).

We used the deviance metric (log~e~(likelihood^2^~reference~/likelihood^2^~model~)), with the naive model as the reference, to determine which model made the better fit to the data. For likelihood calculations to be comparable, we also specified the residuals from the models in the same manner---that is, on the absolute mortality rate scale.

Modelling of data from England, Wales, and the United States
------------------------------------------------------------

We analysed data abstracted from the United Kingdom Office for National Statistics 20th century mortality data for England and Wales,[@ref12] US census and vital statistics databases, and the US National Center for Health Statistics.[@ref13] We used the age and sex specific mortality rates for the actual census years 1950 to 2000. We used the methods proposed by Frost[@ref14] to follow the mortality of three decade-long birth cohorts (1916-25, 1926-35, and 1936-45). We chose these birth cohorts because they included women who reached postmenopausal ages within the 20th century, and these cohorts were relatively unaffected by large scale immigration waves into the United States. We chose the same birth cohorts for the England-Wales data for comparability.

We followed US cohorts in time thus: the census counts and mortality rates for the 1936-45 cohort corresponded with the 5-14 year age group (cohort mid-age rounded to 10 years) in the 1950 census and vital statistics reports, and the 15-24 year age group (cohort mid-age 20 years) in the 1960 reports. We continued this method up to the 75-84 year age group (cohort mid-age 80 years) in the 2000 reports. Similarly, we traced the mortality rates for all three cohorts. We analysed all cause mortality and disease specific mortality rates for heart disease (in men and women) and breast cancer (only in women).

We abstracted mortality data for ischaemic heart disease and breast cancer for the England-Wales cohorts, using International Classification of Diseases codes (table 1[](#tbl1){ref-type="table"}). For the US data source,[@ref13] longitudinal mortality rates over the full analysis period were available for total heart disease rather than for ischaemic heart disease. The National Center for Health Statistics collected breast cancer mortality data only for women older than 25 years.[@ref13] We excluded death rates for individuals older than 85 years because the National Center for Health Statistics placed these deaths into a single group in these datasets. Therefore, we could not assign these individuals to any particular decadal birth cohort. Web appendix 2 shows the full abstracted dataset from the vital statistics sources used to graph and model the data.

###### 

 International Classification of Diseases (ICD) codes for ischaemic and total heart disease and female breast cancer

           Ischaemic heart disease (UK)   Total heart disease (United States)   Breast cancer (UK and United States)
  -------- ------------------------------ ------------------------------------- --------------------------------------
  ICD-6    420.0 to 420.2                 410 to 443                            170
  ICD-7    420.0 to 420.2                 400 to 402, 410 to 443                170
  ICD-8    410 to 414                     390 to 398, 402, 404, 410 to 429      174
  ICD-9    410 to 414                     390 to 398, 402, 404, 410 to 429      174 to 174.9
  ICD-10   I20 to I25                     I00 to I09, I11, I13, I20 to I51      C50

We analysed data separately for men and women. We used the cohort mid-age as the age variable for plotting and regression analysis. We regarded rates for women in cohorts when they aged to 45-54 years (cohort mid-age 50 years) and older to be postmenopausal. The vast majority of menopause occurs during the 45-54 year age period. We also compared the different age-mortality slopes before and after 45 years of age in models 1 and 2, to determine whether the age-mortality trend would change at menopause in women, and at a similar age in men.

We calculated the longitudinal death rates in the cohorts using generalised mixed models. For comparability of model fit between the linear age dependence and the log-linear age dependence, we calculated the explained variance in the mortality rate data on the original scale (Gaussian residual errors). Detailed model equations are presented in web appendix 1. If we saw a secular trend by calendar year, we would model such a trend as secondary analysis.

To compare the models, we tabulated deviance statistics and the difference in the Akaike information criterion[@ref15] with the naive linear model as the reference. We considered a reduction of at least four logarithmic units in the Akaike information criterion to be a significant improvement, and a reduction of at least 10 logarithmic units to be a highly significant improvement in model fit (simplified from Burnham and Anderson's multiple level criteria[@ref16]).

Model fitting was undertaken using the generalised linear latent and mixed models software implemented in Stata (version 10, StataCorp, College Station, TX, USA). Web appendix 1 also describes the sensitivity analysis.

Results
=======

Table 2[](#tbl2){ref-type="table"} shows the census counts of men and women of the three birth cohorts (1916-25, 1926-35, and 1936-45) for 1950 and 2000, by country. Figure 1[](#fig1){ref-type="fig"} shows the ischaemic heart disease mortality of the three birth cohorts in England and Wales as they aged in the 20th century, either on the absolute scale or the logarithmic scale.

![**Fig 1** Ischaemic heart disease mortality in England and Wales by age plotted on absolute scale (top panels) and on logarithmic scale (bottom panels)](vaid859264.f1_default){#fig1}

###### 

 Populations of birth cohorts (in thousands) in census years 1950 and 2000

  Birth cohort   Census year   England and Wales          United States            
  -------------- ------------- ------------------- ------ --------------- -------- --------
  1916-25        1950          1681                1673                   12 162   11 597
                 2000          1050                741                    7482     4879
  1925-35        1950          1390                1346                   11 181   10 918
                 2000          1198                1100                   10 088   8303
  1935-45        1950          1501                1569                   11 944   12 375
                 2000          1455                1429                   12 629   11 645

For the England-Wales birth cohorts, all absolute mortality curves showed an upward-bent profile, whereas the log**-**mortality curves did not show a prominent upward bend. Among women, none of the cohorts showed a substantial upward shift in slope in the log-mortality curves due to ischaemic heart disease around the time of menopause (45-55 years), and there was a log-linear increase in mortality throughout all ages. Among men, the log-linear increase in mortality was strongly blunted after age 45 years in all birth cohorts. For both men and women, we saw a reduction in the overall mortality of successive birth cohorts at advanced ages. US data for total heart disease mortality also showed the same pattern (fig 2[](#fig2){ref-type="fig"}).

![**Fig 2** Total heart disease mortality in the United States by age plotted on absolute scale (top panels) and on logarithmic scale (bottom panels)](vaid859264.f2_default){#fig2}

Figure 3[](#fig3){ref-type="fig"} shows female breast cancer mortality on the absolute and logarithmic scales in the England-Wales and the US birth cohorts. As with previous cross sectional analyses,[@ref1] we observed a distinct difference in slope gradients before and after age 45 years in the log-mortality rate plots. We did not see any cohort-wide reductions in breast cancer mortality for later cohorts, especially at young ages. However, there is a suggestion that the log-mortality curves could have flattened in the 1990s for all cohorts (that is, at different ages for each of the cohorts). This finding could be a secular phenomenon related to the adoption of breast cancer screening programmes in the early 1990s.[@ref17] [@ref18] [@ref19]

![**Fig 3** Female breast cancer mortality in England and Wales and the United States plotted on absolute scale (top panels) and on logarithmic scale (bottom panels)](vaid859264.f3_default){#fig3}

Table 3[](#tbl3){ref-type="table"} shows the association of mortality with age by longitudinal data analysis for the various models and their goodness of fit. For all cause mortality and heart disease mortality, the log-mortality models fit the data much better than the absolute mortality models. Interestingly, women showed a non-significant deceleration in the log-mortality curves after age 45 years, whereas men showed a significant deceleration after age 45 years. For breast cancer mortality in women, the log-mortality model showed the best fit, with a significant deceleration of age related increase in mortality after age 45 years. We also identified a strong secular trend for reduced breast cancer mortality after 1990 (fig 3). After adjusting for birth cohort and age, breast cancer mortality was 25% lower after 1990. Web appendix 3 shows similar results of the analyses of total heart disease and breast cancer mortality in US data.

###### 

Ischaemic heart disease mortality and female breast cancer mortality in England-Wales birth cohorts, by sex

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Model                                    Ischaemic heart disease               Breast cancer (women only)                                                      
  ---------------------------------------- ------------------------- ----------- ---------------------------- ---------------- ----------- -- ------------------ -----------
  Linear (overall slope)                   22.4, P\<0.001            Reference                                10.3, P\<0.001   Reference      2.5, P\<0.001      Reference

  Log-linear (overall slope)               5.8%, P\<0.001            −37\                                     7.9%, P\<0.001   −58\           4.2%, P\<0.001     −5\
                                                                     −37                                                       −58                               −5

  **Linear with spline‡**                                                                                                                                        

  Slope before age 45 years                −2.1, P=0.61              −16\                                     −4.2, P=0.14     −19\           1.4, P\<0.001      −5\
                                                                     −14                                                       −17                               −3

  Difference in slope after age 45 years   48.9, P\<0.001                                                     29.0, P\<0.001                  2.1, P\<0.001      

  **Log-linear with spline‡**                                                                                                                                    

  Slope before age 45 years                30.3%, P=0.014            −50\                                     39.3%, P=0.32    −62\           19.3%, P\<0.001    −31\
                                                                     −48                                                       −60                               −29

  Difference in slope after age 45 years   −25.1%, P=0.042                                                    −31.6%, P=0.43                  −16.7%, P\<0.001   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AIC=Akaike information criterion.

\*β= slope or change in slope after age 45 years compared with the slope before age 45 years. P=probability for Wald test of significance of the null hypothesis that β equals 0. Linear slopes represent increase in deaths per 100 000 per age-year. Log-linear slopes represent percentage increase in mortality per age-year.

†A lower or more negative deviance indicates better model fit. The difference in AIC penalises the deviance metric for the addition of extra parameters in the interest of model parsimony.

‡Spline models included the variable "age-spline" was equal to 0 if cohort mid-age was under 50 years (that is, younger than the 45-54 year cohort), and equal to the cohort mid-age for older ages.

Discussion
==========

We have shown that analysis using log-linear mortality rates is consistent with the plausible biological mechanism of reparative reserve. By using the most comprehensive and complete longitudinal mortality dataset available for England and Wales as well as for the United States, in the 20th century, we have shown that log-linear models fit the mortality data much better than a simple linear model.

Comparison with previous findings from cross sectional analyses
---------------------------------------------------------------

Our longitudinal cohort analysis confirms previously reported cross sectional age-mortality associations.[@ref4] [@ref5] However, our findings are more convincing than those of previous analyses, because age trends are best studied by following cohorts of individuals over their lifetime rather than comparing different individuals of the same and different ages in a cross section of the population.

Issues of unaccounted secular trends and cohort effects have clouded the interpretation of cross sectional mortality analyses, and are resolved by our longitudinal analysis. Cross sectional analyses would not have detected our finding that cohorts born later in the 20th century have lower cardiovascular mortality at higher ages than cohorts born earlier in the 20th century. In addition, our analysis showed a secular change in breast cancer mortality after the 1990s, which could not have been detected with cross sectional analysis.

We showed that there was no sharp increase in slope or step increase in ischaemic heart disease mortality among women at menopausal ages. The mortality steadily increased across all ages in adult women, whereas the corresponding increase was blunted at older ages in men. These observations also applied to three birth cohorts in different countries, presumably with varying secular life experiences in terms of lifestyle, knowledge of health risks (such as smoking), and disease and risk factor treatments. These data strengthen the conclusions of previous cross sectional analyses.[@ref5] In our longitudinal birth cohort analyses, the age effect is not confounded by the decreasing overall heart disease risk of successive birth cohorts. Therefore, the flattening of the curves at higher ages in men should be justifiably considered a biological phenomenon rather than an artefact of cross sectional analysis.

Potential explanations for age-mortality trends
-----------------------------------------------

The steady log-linear increase in age related heart disease mortality in men and women suggests cumulative effects of lifelong vascular injury and failure of repair mechanisms. However, this interpretation is based on mathematical derivation and published biological studies in small samples, and not measurements in these national cohorts.

Because both men and women in our study showed upward bent curves on the absolute mortality scale, the upward bend cannot be interpreted as being attributable to menopause. In fact, men showed a steeper age-mortality slope than women as young adults, which flattened into middle age. As previously suggested,[@ref1] the accelerated risk in men at younger ages compared with women at the same ages could indicate an accelerated failure of the reparative reserve in young men, rather than the relative protection of premenopause hormonal effects in young women. Because we analysed only vital statistics data (and therefore could not analyse individual cardiovascular risk factors or the individual timings of menopause in women), this biological explanation is speculative. However, our proposed mechanism is consistent with a study reporting that the rate of telomere loss per age-year was equal in adult men (0.038 kb/age-year) and women (0.036 kb/age-year) at all ages between 25 and 75 years.[@ref20] But in that study,[@ref20] age adjusted telomere lengths were substantially shorter, by 0.28 kb, in men than women. This difference is equivalent to the telomere shortening process being shifted 7.6 age-years in men, compared with women.

Although we did not see any proportional acceleration of heart disease mortality at menopause, the absolute mortality still increases at all ages in women, including the postmenopausal period. Thus the current concern about cardiovascular disease among women in the ageing US population is fully justified, but with the focus on lifetime risk rather than primarily at menopause.

Pike and colleagues discussed that carcinogenesis, being a multistage process, would be expected to have a log-linear age-mortality association, and they showed such an association for colorectal cancer mortality.[@ref7] From new cell biological insights,[@ref8] [@ref9] [@ref10] we generalised this paradigm to all chronic senescent processes, including the multistage accumulation of carcinogenic trauma, as well as vascular damage under the general concept of the failure of reparative reserve. Our models confirm the deceleration of breast cancer mortality around the age of menopause as previously shown.[@ref5] [@ref7] This finding is consistent with our biological model that non-communicable diseases could represent a failure of the reparative reserve. The cyclical hyperplasia and hypoplasia of breast tissue (evidence reviewed by Pike et al[@ref7]) before menopause is expected to strain the reparative reserve for this organ more than after menopause. The demands on the reparative reserve could vary with age for different organ systems, and for the two sexes, modulating the rate of reduction in reparative reserve over age. Similarly, known cardiovascular risk factors such as smoking, hypercholesterolaemia, and hypertension might damage vascular tissue and therefore increase the demand for repair. This would consequently alter the rate of loss of reparative reserve. We recognise that a full explanation of the age association of cause specific mortality due to chronic senescent conditions would require modelling these factors. However, the log-linear mortality-age model had a much better fit than the simple linear model.

Census and mortality data
-------------------------

A major strength of this analysis is the comprehensive nature of the British and US census and mortality data. However, there are specific caveats. Although we examined ischaemic heart disease mortality in the British data, cause specific mortality data were not separately available for the disease in the US data source for periods before 1980.[@ref13] However, the findings were substantially similar in the two analyses. Ischaemic heart disease constituted most of the age adjusted total heart disease mortality in the United States for years when the data were separately available---for example, of total heart mortality in 2000, 75.4% in men and 69.5% in women were due to ischaemic heart disease. Thus the US and British data were similarly interpretable. Total heart disease mortality also includes deaths due to heart failure, which is a chronic senescent condition associated with the loss of progenitor cells,[@ref21] [@ref22] and our biological discussion applies to heart failure as well.

Another consideration is that the birth cohorts were open cohorts due to immigration and emigration. However, individuals who migrated to the United States as adults in the 1900-20 wave of immigration would not greatly affect the earliest birth cohort (1916-25) of this analysis. The recent major immigration wave of 1980-2000 included mostly young adults and added little to the population aged 45 years and older,[@ref23] and should not affect our latest birth cohort. In addition, the US and Britain have different migration experiences, yet we found similar results between the two datasets, suggesting that immigration patterns are unlikely to affect the conclusions and interpretation of our analysis.

Conclusions
-----------

We have shown that each successive birth cohort in England, Wales, and the United States in 1916-45 had lower total and heart disease mortality over their lifetimes. Heart disease mortality in women increased exponentially throughout all ages, with no special step increase at menopausal ages. This finding sharply contrasts with breast cancer mortality in women, which decelerated drastically at menopause. The increase in heart disease mortality due to age in men was greater during early adulthood than that in women, and the age related increase was blunted at advanced ages.

Efforts to improve cardiac health in women should focus on lifetime risk rather than risk only after menopause. Our proposed biological model showing that fatal events are a result of a loss of reparative reserve fitted the mortality data far better than a model of linear age related increases in absolute mortality rates. This finding should serve as a point of departure for more refined models of age related mortality.

### What is already known on this topic

1.  Although heart disease mortality increases with age, it is lower in women than in men

2.  It has been suggested that this protective effect is due to female sex hormones, and the protection is therefore lost at menopause

### What this study adds

1.  Heart disease mortality in women increased exponentially with age, with no acceleration at menopause. In men, there was a rapid increase during young adulthood followed by reduced rates of increase

2.  The early rapid acceleration in male heart disease mortality could explain these sex differences rather than menopausal changes in women

3.  Efforts to improve cardiac health in women should focus on their lifetime risk rather than only after menopause
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